Finch Therapeutics Group Inc banner

Finch Therapeutics Group Inc
OTC:FNCH

Watchlist Manager
Finch Therapeutics Group Inc Logo
Finch Therapeutics Group Inc
OTC:FNCH
Watchlist
Price: 9.5 USD Market Closed
Market Cap: $15.3m

Wall Street
Price Targets

FNCH Price Targets Summary
Finch Therapeutics Group Inc

There are no price targets for FNCH.
Lowest
Price Target
Not Available
Average
Price Target
Not Available
Highest
Price Target
Not Available
Finch Therapeutics Group Inc Competitors:
Price Targets
HCAT
Health Catalyst Inc
85% Upside
EXPO
Exponent Inc
34% Upside
MEDP
Medpace Holdings Inc
1% Upside

Revenue
Forecast

-76% / Year
Past Growth
2 805% / Year
Estimated Growth
Estimates Accuracy
-10%
Average Miss
-76% / Year
Past Growth
2 805% / Year
Estimated Growth
Estimates Accuracy
-10%
Average Miss

For the last 3 years the compound annual growth rate for Finch Therapeutics Group Inc's revenue is -76%. The projected CAGR for the next 2 years is 2 805%.

Operating Income
Forecast

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-12%
Average Miss
N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-12%
Average Miss

Net Income
Forecast

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
14%
Average Beat
N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
14%
Average Beat
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is FNCH's stock price target?
Not Available

FNCH doesn't have any price targets made by Wall Street professionals.

What is Finch Therapeutics Group Inc's Revenue forecast?
Projected CAGR
2 805%

For the last 3 years the compound annual growth rate for Finch Therapeutics Group Inc's revenue is -76%. The projected CAGR for the next 2 years is 2 805%.

Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett